Patrick Chun

[section title=”Three Columns With Header” id=”section4″ wide=true typography_md=”Text {line-height: 22.85714286px;font-size: 16px;}H3 {line-height: 28.57142858px;font-size: 20px;}” typography_sm=”Text {line-height: 22.85714286px;font-size: 16px;}H3 {line-height: 22.85714286px;font-size: 16px;}” typography_xs=”Text {line-height: 23.8px;}H1 {line-height: 51.42857144px;font-size: 36px;}” css=”padding-bottom:3em;padding-top:1em;” typography=”Text {line-height: 36px;text-align: center;color: #555555;font-size: 18px;font-weight: 400;}H4 {text-transform: none;color: #002061;}H3 {line-height: 34.2857143px;font-size: 24px;font-weight: 600;text-transform: uppercase;}H1 {line-height: 85.71428574px;text-transform: uppercase;font-size: 60px;font-weight: normal;letter-spacing: 1px;}”]
[background_width][columns auto_height=1 vertical_align=”top” add_margins=true spacing_css_xs=”margin-top:-15px;margin-bottom:-15px;padding-top:15px;padding-bottom:15px;height:calc(130%);” spacing_css=”height:calc(110%);margin:-5px;padding:5px;”]
[column width_xs=”12″ css_xs=”padding:10px;” css=”padding:1em;”]
[image_scaling css=”background-position:center center;background-repeat:no-repeat;background-size:cover;”]
[image image_style=”imagestyles-23″ image=”https://amphivena.com/wp-content/uploads/2019/07/amphivena-patrick-web.jpg” css_xs=”width:75%;” css=”width:20%;”][/image][/image_scaling]

[text tag=”h4″ typography_xs=”Text {line-height: 34.2857143px;font-size: 24px;}” typography=”Text {line-height: 42.85714287px;font-family: Lato, Arial, ‘Arial Unicode MS’, Helvetica, sans-serif;font-size: 30px;}”]Patrick Chun, M.D.[/text]

[text tag=”h4″ typography_xs=”Text {line-height: 28.57142858px;font-size: 20px;}” typography=”Text {line-height: 28.57142858px;font-family: Lato, Arial, ‘Arial Unicode MS’, Helvetica, sans-serif;font-size: 20px;}”]Vice President, Clinical Development[/text]

[separator content_type=”none” text=”Caption” text_tag=”span” align=”center” content_align=”center” href=”#” image=”https://cstatic.themler.io/themler/483/images/defaultImage.jpg” css=”padding:20px 0px;” image_css=”display:inline-block;” content_css=”margin-left:30px;margin-right:30px;” content_typography=”Text {color: #777777;}” line_css=”width:25%;border-top:1px solid #dddddd;”][/separator]

[text tag=”p” css_xs=”width:100%;” css=”width:70%;display:inline-block;margin-top:12px;” typography=”Text {line-height: 35px;text-align: justify;}”]Patrick Chun, M.D. is a board-certified Hematologist and Oncologist with drug development experience in both large pharma and small biotech. Patrick began his career at Merck & Co., where he was charged with the development of a small-molecule ERK-inhibitor, as well as running early- and late-stage studies in melanoma indications for pembrolizumab (KEYTRUDA), which was the first PD-1 inhibitor to be approved by the FDA.  He then moved on to Gilead Sciences, where he led the clinical development of the bromodomain-inhibitor program (GS-5829) across oncology indications, as well as supporting the clinical development of antibodies against novel tumor microenvironment targets. Immediately prior to joining Amphivena, Patrick was head of clinical development at a small privately held biotechnology company located in San Diego, where he led the first clinical programs from pre-IND through Phase 1 in multiple oncology indications. Patrick holds a B.S. (Chemistry) and M.D. from Michigan State University, trained in Internal Medicine at Brown University, and completed his fellowship in hematology and oncology at UCLA.[/text]
[/column]
[/columns][/background_width]
[/section]

[section title=”Three Columns With Header” id=”section4″ wide=true typography_md=”Text {line-height: 22.85714286px;font-size: 16px;}H3 {line-height: 28.57142858px;font-size: 20px;}” typography_sm=”H3LinkPassive {line-height: 22.85714286px;font-size: 16px;}” typography_xs=”Text {line-height: 23.8px;}H1 {line-height: 51.42857144px;font-size: 36px;}” css=”padding-bottom:0em;padding-top:1em;background-color:#ffffff;” typography=”Text {line-height: 27.2px;text-align: center;color: #002061;font-size: 16px;font-weight: 400;font-family: Lato, Arial, ‘Arial Unicode MS’, Helvetica, sans-serif;}TextLinkPassive {color: #002061;}TextLinkHovered {color: #0070c0;}H3 {line-height: 25.71428573px;font-size: 18px;font-weight: 600;text-transform: uppercase;color: #002061;}H3LinkPassive {line-height: 22.85714286px;font-size: 16px;}H1 {line-height: 42.85714287px;text-transform: uppercase;font-size: 30px;letter-spacing: 1px;font-style: normal;font-weight: 600;color: #002061;font-family: Lato, Arial, ‘Arial Unicode MS’, Helvetica, sans-serif;}”]
[columns auto_height=1 vertical_align=”top” add_margins=true spacing_css_xs=”margin-top:-15px;margin-bottom:-15px;padding-top:15px;padding-bottom:15px;height:calc(130%);” spacing_css=”height:calc(110%);margin:-5px;padding:5px;”]
[column width_xs=”12″]
[html ]

[/html]

[text tag=”h1″ typography=”Text {font-weight: normal;font-family: Lato, Arial, ‘Arial Unicode MS’, Helvetica, sans-serif;color: #0070c0;}”]Leadership[/text]

[separator content_type=”none” text=”Caption” text_tag=”span” align=”center” content_align=”center” href=”#” image=”https://cstatic.themler.io/themler/480/images/defaultImage.jpg” css=”padding:10px 0px;” image_css=”display:inline-block;” content_css=”margin-left:30px;margin-right:30px;” content_typography=”Text {color: #777777;}” line_css_xs=”width:10%;” line_css=”width:5%;border-top:2px solid #000000;”][/separator]
[/column]

[column width_sm=”3″ css=”padding:1em;”]
[image href=”https://amphivena.com/curtis-l-ruegg-bio/” target=”_self” alt=”Curtis L. Ruegg” image=”https://amphivena.com/wp-content/uploads/amphivena-therapeutics-ceo-curtis-l-ruegg-phd.jpg” css_sm=”width:150px;height:155px;” css=”height:195px;width:195px;”][/image]

[text tag=”h3″ css=”margin-bottom:0px;” typography=”Text {line-height: 25.71428572px;font-size: 18px;}”]Curtis Ruegg, Ph.D.
[/text]

[text tag=”p” css=”margin-top:0px;margin-bottom:0px;”]CEO & President[/text]
[/column]

[column width_sm=”3″ css=”padding:1em;”]
[image href=”https://amphivena.com/victoria-smith-bio/” target=”_self” alt=”Victoria Smith” image=”https://amphivena.com/wp-content/uploads/2019/05/amphivena-victoria.png” css_sm=”width:145px;height:156px;” css=”width:180px;height:193px;”][/image]

[text tag=”h3″ css=”margin-bottom:0px;” typography=”Text {line-height: 25.71428572px;font-size: 18px;}”]


Victoria Smith, Ph.D.
[/text]

[text tag=”p” css=”margin-top:0px;”]


Chief Scientific Officer [/text]
[/column]

[column width_sm=”3″ css=”position:relative;padding:1em;”]
[image href=”https://amphivena.com/patrick-chun-bio/” target=”_self” alt=”Patrick Chun” image=”https://amphivena.com/wp-content/uploads/2019/07/amphivena-patrick-web.jpg” css_sm=”width:150px;height:152px;” css=”height:193px;width:191px;”][/image]

[text tag=”h3″ css=”margin-bottom:1px;” typography=”Text {line-height: 25.71428572px;font-size: 18px;}”]


Patrick Chun, M.D.
[/text]

[text tag=”p” css=”margin-top:1px;margin-bottom:0px;”]


Vice President[/text]

[text tag=”p” css=”margin-top:-8px;”]Clinical Development [/text]
[/column]

[column width_sm=”3″ css=”position:relative;padding:1em;”]
[image href=”https://amphivena.com/amy-penticoff-bio/” target=”_self” alt=”Amy Penticoff” image=”https://amphivena.com/wp-content/uploads/2019/05/amphivena-amy.png” css_sm=”width:150px;height:154px;” css=”width:189px;height:194px;”][/image]

[text tag=”h3″ css=”margin-bottom:0px;” typography=”Text {line-height: 25.71428572px;font-size: 18px;}”]


Amy penticoff, MBA
[/text]

[text tag=”p” css=”margin-top:0px;margin-bottom:0px;”]


Vice President[/text]

[text tag=”p” css=”margin-top:-8px;”]Technical Operations [/text]
[/column]
[/columns]
[/section]